CYTK Quote, Financials, Valuation and Earnings

Biogen has a net margin of -886.28% compared to Cytokinetics's net margin of 10.87%. Cytokinetics's return on equity of -- beat Biogen's return on equity of 10.33%.

Cytokinetics has a consensus price target of $78.40, signalling upside risk potential of 81.52%. On the other hand Biogen has an analysts' consensus of $200.12 which suggests that it could grow by 44.62%. Given that Cytokinetics has higher upside potential than Biogen, analysts believe Cytokinetics is more attractive than Biogen.

Cytokinetics has a beta of 0.949, which suggesting that the stock is 5.057% less volatile than S&P 500. In comparison Biogen has a beta of 0.012, suggesting its less volatile than the S&P 500 by 98.773%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Cytokinetics quarterly revenues are $16.9M, which are smaller than Biogen quarterly revenues of $2.5B. Cytokinetics's net income of -$150M is lower than Biogen's net income of $266.7M. Notably, Cytokinetics's price-to-earnings ratio is -- while Biogen's PE ratio is 12.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 261.24x versus 2.09x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Bristol-Myers Squibb has a net margin of -886.28% compared to Cytokinetics's net margin of 0.58%. Cytokinetics's return on equity of -- beat Bristol-Myers Squibb's return on equity of -46.27%.

Cytokinetics has a consensus price target of $78.40, signalling upside risk potential of 81.52%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $61.24 which suggests that it could grow by 2.04%. Given that Cytokinetics has higher upside potential than Bristol-Myers Squibb, analysts believe Cytokinetics is more attractive than Bristol-Myers Squibb.

Cytokinetics has a beta of 0.949, which suggesting that the stock is 5.057% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.435, suggesting its less volatile than the S&P 500 by 56.528%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 4.03% to investors and pays a quarterly dividend of $0.62 per share. Cytokinetics pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out -54.35% of its earnings as a dividend.

Cytokinetics quarterly revenues are $16.9M, which are smaller than Bristol-Myers Squibb quarterly revenues of $12.3B. Cytokinetics's net income of -$150M is lower than Bristol-Myers Squibb's net income of $72M. Notably, Cytokinetics's price-to-earnings ratio is -- while Bristol-Myers Squibb's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 261.24x versus 2.52x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of -886.28% compared to Cytokinetics's net margin of -103.5%. Cytokinetics's return on equity of -- beat Rhythm Pharmaceuticals's return on equity of -178.94%.

Cytokinetics has a consensus price target of $78.40, signalling upside risk potential of 81.52%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $75.25 which suggests that it could grow by 37.32%. Given that Cytokinetics has higher upside potential than Rhythm Pharmaceuticals, analysts believe Cytokinetics is more attractive than Rhythm Pharmaceuticals.

Cytokinetics has a beta of 0.949, which suggesting that the stock is 5.057% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.300, suggesting its more volatile than the S&P 500 by 130.019%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

Cytokinetics quarterly revenues are $16.9M, which are smaller than Rhythm Pharmaceuticals quarterly revenues of $41.8M. Cytokinetics's net income of -$150M is lower than Rhythm Pharmaceuticals's net income of -$43.3M. Notably, Cytokinetics's price-to-earnings ratio is -- while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 261.24x versus 25.69x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of -886.28% compared to Cytokinetics's net margin of -747.33%. Cytokinetics's return on equity of -- beat Sage Therapeutics's return on equity of -63.59%.

Cytokinetics has a consensus price target of $78.40, signalling upside risk potential of 81.52%. On the other hand Sage Therapeutics has an analysts' consensus of $8.05 which suggests that it could fall by -2.83%. Given that Cytokinetics has higher upside potential than Sage Therapeutics, analysts believe Cytokinetics is more attractive than Sage Therapeutics.

Cytokinetics has a beta of 0.949, which suggesting that the stock is 5.057% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.817, suggesting its less volatile than the S&P 500 by 18.337%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Cytokinetics quarterly revenues are $16.9M, which are larger than Sage Therapeutics quarterly revenues of $12.8M. Cytokinetics's net income of -$150M is lower than Sage Therapeutics's net income of -$95.8M. Notably, Cytokinetics's price-to-earnings ratio is -- while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 261.24x versus 12.20x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.